Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Prostatic Intraepithelial Neoplasia 1Male Urogenital Diseases 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × Lycopene × Clear all
NCT01882985 2021-01-05

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

University of California, Irvine

Phase 2 Completed
14 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00450749 2019-12-18

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
10 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

NCT01443026 2019-11-19

The Effects of Lycopene on High Risk Prostatic Tissue

University of Illinois at Chicago

Phase 2 Completed
66 enrolled 8 charts
Genitourinary

Prostatic Neoplasms, Prostatic Intraepithelial Neoplasia, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡